Alexander Gg Turpie

Summary

Affiliation: McMaster University
Country: Canada

Publications

  1. ncbi request reprint Venous thromboembolism prophylaxis: role of factor xa inhibition by fondaparinux
    A G G Turpie
    Department of Medicine, Hamilton Health Sciences, General Hospital, Hamilton, Ontario, Canada
    Surg Technol Int 13:261-7. 2004
  2. ncbi request reprint BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study
    A G G Turpie
    HHS General Hospital, Hamilton, Canada
    J Thromb Haemost 3:2479-86. 2005
  3. doi request reprint Venous and arterial thrombosis--pathogenesis and the rationale for anticoagulation
    Alexander G G Turpie
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Thromb Haemost 105:586-96. 2011
  4. doi request reprint A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment
    Alexander G G Turpie
    Alexander G G Turpie, MD, Department of Medicine, Hamilton Health Sciences, General Division, 237 Barton Street East, Hamilton, Ontario, Canada, Tel 1 905 929 4385, Fax 1 905 628 9505, E mail
    Thromb Haemost 111:94-102. 2014
  5. doi request reprint Venous thromboembolism risk in ischemic stroke patients receiving extended-duration enoxaparin prophylaxis: results from the EXCLAIM study
    Alexander G G Turpie
    Department of Medicine, McMaster University, Hamilton Health Sciences General Hospital, 237 Barton Street East, Hamilton, Ontario L8L 2X2, Canada
    Stroke 44:249-51. 2013
  6. doi request reprint Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor
    Alexander G G Turpie
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Thromb Haemost 108:876-86. 2012
  7. pmc Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery
    Alexander G G Turpie
    Department of Medicine, General Division, Hamilton Health Sciences, Ontario, Canada
    Vasc Health Risk Manag 8:363-70. 2012
  8. ncbi request reprint Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients
    Walter Ageno
    University of Insubria Ospedale di Circolo, Varese, Italy
    Thromb Haemost 107:1027-34. 2012
  9. doi request reprint Rivaroxaban for the prevention and treatment of venous thromboembolism
    Alexander G G Turpie
    McMaster University, 237 Barton Street East, Hamilton, Ontario, Canada
    Fundam Clin Pharmacol 26:33-8. 2012
  10. ncbi request reprint Burden of disease: medical and economic impact of acute coronary syndromes
    Alexander G G Turpie
    Hamilton Health Sciences General Hospital, 237 Barton St E, Hamilton, Ontario, Canada L8L 2X2
    Am J Manag Care 12:S430-4. 2006

Collaborators

Detail Information

Publications83

  1. ncbi request reprint Venous thromboembolism prophylaxis: role of factor xa inhibition by fondaparinux
    A G G Turpie
    Department of Medicine, Hamilton Health Sciences, General Hospital, Hamilton, Ontario, Canada
    Surg Technol Int 13:261-7. 2004
    ..4% (p<0.001). Four-week fondaparinux could become the standard thromboprophylaxis after hip fracture surgery. Fondaparinux is the first selective factor Xa inhibitor approved for use in thromboprophylaxis after orthopedic surgery...
  2. ncbi request reprint BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study
    A G G Turpie
    HHS General Hospital, Hamilton, Canada
    J Thromb Haemost 3:2479-86. 2005
    ..BAY 59-7939, a novel, oral, direct factor Xa inhibitor, is in clinical development for the prevention of venous thromboembolism (VTE), a frequent complication following orthopaedic surgery...
  3. doi request reprint Venous and arterial thrombosis--pathogenesis and the rationale for anticoagulation
    Alexander G G Turpie
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Thromb Haemost 105:586-96. 2011
    ..Based on scientific rationale, both factor Xa and thrombin are viable targets for effective anticoagulation...
  4. doi request reprint A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment
    Alexander G G Turpie
    Alexander G G Turpie, MD, Department of Medicine, Hamilton Health Sciences, General Division, 237 Barton Street East, Hamilton, Ontario, Canada, Tel 1 905 929 4385, Fax 1 905 628 9505, E mail
    Thromb Haemost 111:94-102. 2014
    ..44% versus 0.33% (weighted) in the propensity score-adjusted analysis (OR 1.35; 95% CI 0.94-1.93), respectively.This study in unselected patients confirmed the favourable benefit-risk profile of rivaroxaban seen in the RECORD programme. ..
  5. doi request reprint Venous thromboembolism risk in ischemic stroke patients receiving extended-duration enoxaparin prophylaxis: results from the EXCLAIM study
    Alexander G G Turpie
    Department of Medicine, McMaster University, Hamilton Health Sciences General Hospital, 237 Barton Street East, Hamilton, Ontario L8L 2X2, Canada
    Stroke 44:249-51. 2013
    ....
  6. doi request reprint Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor
    Alexander G G Turpie
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Thromb Haemost 108:876-86. 2012
    ....
  7. pmc Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery
    Alexander G G Turpie
    Department of Medicine, General Division, Hamilton Health Sciences, Ontario, Canada
    Vasc Health Risk Manag 8:363-70. 2012
    ..XAMOS was started in 2009 and will complete recruitment and follow-up in 2011...
  8. ncbi request reprint Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients
    Walter Ageno
    University of Insubria Ospedale di Circolo, Varese, Italy
    Thromb Haemost 107:1027-34. 2012
    ....
  9. doi request reprint Rivaroxaban for the prevention and treatment of venous thromboembolism
    Alexander G G Turpie
    McMaster University, 237 Barton Street East, Hamilton, Ontario, Canada
    Fundam Clin Pharmacol 26:33-8. 2012
    ..With encouraging data already emerging, the promise of a simplified single-drug approach for VTE treatment is on the horizon...
  10. ncbi request reprint Burden of disease: medical and economic impact of acute coronary syndromes
    Alexander G G Turpie
    Hamilton Health Sciences General Hospital, 237 Barton St E, Hamilton, Ontario, Canada L8L 2X2
    Am J Manag Care 12:S430-4. 2006
    ..More recently developed antithrombotic agents may have clinical and economic advantages over older therapies...
  11. pmc Prevention of venous thromboembolism in medically ill patients: a clinical update
    Alexander G G Turpie
    Department of Medicine, Hamilton General Hospital, HHS McMaster Clinic, 237 Barton Street East, Hamilton, Ontario L8L 2X2, Canada
    Postgrad Med J 82:806-9. 2006
    ....
  12. ncbi request reprint Extended duration of thromboprophylaxis in acutely ill medical patients: optimizing therapy?
    A G G Turpie
    Department of Medicine, Hamilton Health Sciences General Hospital, Hamilton, ON, Canada
    J Thromb Haemost 5:5-11. 2007
    ....
  13. ncbi request reprint The safety of fondaparinux for the prevention and treatment of venous thromboembolism
    Alexander G G Turpie
    General Division, Hamilton Health Sciences Corporation, 237 Barton Street East, Hamilton, ON, L8L 2X2, Canada
    Expert Opin Drug Saf 4:707-21. 2005
    ..In conclusion, due to its superior efficacy and satisfactory safety, fondaparinux may substantially improve the prevention and treatment of venous thrombosis...
  14. ncbi request reprint Superiority of fondaparinux over enoxaparin in preventing venous thromboembolism in major orthopedic surgery using different efficacy end points
    Alexander G G Turpie
    Department of Medicine, Hamilton Health Sciences General Hospital, 237 Barton St East, Hamilton, ON, L8L 2X2, Canada
    Chest 126:501-8. 2004
    ....
  15. ncbi request reprint Thromboprophylaxis in medical patients: the role of low-molecular-weight heparin
    Alexander G G Turpie
    Hamilton Health Sciences, Hamilton General Hospital, 237 Barton Street East, Hamilton, Ontario, Canada, L8L 2X2
    Thromb Haemost 92:3-12. 2004
    ..These studies provide solid evidence for the widespread use of thromboprophylaxis in medical patients...
  16. ncbi request reprint The design of venous thromboembolism prophylaxis trials: fondaparinux is definitely more effective than enoxaparin in orthopaedic surgery
    A G G Turpie
    Department of Medicine, Hamilton Health Sciences General Hospital, Hamilton, Ontario, Canada
    Int J Clin Pract 58:483-93. 2004
    ..Fondaparinux used according to its approved regimen provides a simple, easy-to-use, effective and safe post-operative regimen for all orthopaedic surgery patients...
  17. pmc Fondaparinux in the management of patients with ST-elevation acute myocardial infarction
    Alexander G G Turpie
    Hamilton Health Sciences Corporation General Division, Hamilton, ON, Canada
    Vasc Health Risk Manag 2:371-8. 2006
    ..Overall, the data from the OASIS studies showed that fondaparinux 2.5 mg may represent a new anticoagulant standard in patients with acute coronary syndromes...
  18. ncbi request reprint Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases
    Alexander G G Turpie
    HHS General Hospital, Hamilton, Canada
    Arterioscler Thromb Vasc Biol 27:1238-47. 2007
    ..It is hoped that, before long, these anticoagulants will allow us to enter an era of convenient, oral anticoagulation, without the need for regular monitoring or dose adjustment...
  19. doi request reprint Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies
    Alexander G G Turpie
    McMaster University, Hamilton, Ontario, Canada
    Thromb Haemost 105:444-53. 2011
    ....
  20. doi request reprint Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial
    Alexander G G Turpie
    McMaster University, Hamilton, Ontario L8L 2X2, Canada
    Lancet 373:1673-80. 2009
    ..We aimed to test the efficacy and safety of oral rivaroxaban for the prevention of venous thromboembolism after total knee arthroplasty...
  21. doi request reprint Pharmacokinetic and clinical data supporting the use of fondaparinux 1.5 mg once daily in the prevention of venous thromboembolism in renally impaired patients
    Alexander G G Turpie
    Department of Medicine, Hamilton Health Sciences, 237 Barton Street East, Hamilton, Ontario, Canada
    Blood Coagul Fibrinolysis 20:114-21. 2009
    ..5 mg in patients with normal renal function. This dosage regimen showed a favorable efficacy/safety clinical profile and should be appropriate in preventing venous thromboembolism in patients with moderate renal impairment...
  22. ncbi request reprint A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT)
    Alexander G G Turpie
    McMaster University, Hamilton, Ontario, Canada
    Thromb Haemost 101:68-76. 2009
    ..Betrixaban demonstrated antithrombotic activity and appeared well tolerated in knee replacement patients at the doses studied...
  23. doi request reprint The top 4 advances in antithrombotic care in the last year
    Alexander G G Turpie
    McMaster University, Hamilton, Canada
    Thromb Res 123:S2-6. 2008
    ..Finally, the approval of new practice-changing, paradigm-shifting oral anticoagulants is on the horizon. This article will review the top 4 advances in antithrombotic care and discuss their impact on the clinical management of VTE...
  24. ncbi request reprint New oral anticoagulants in atrial fibrillation
    Alexander G G Turpie
    Department of Medicine, HHS General Hospital, 237 Barton Street East, Hamilton, Ontario, Canada L8L 2X2
    Eur Heart J 29:155-65. 2008
    ..If approved, they may represent the next generation of anticoagulants, by providing new therapeutic options for stroke prevention in patients with AF...
  25. ncbi request reprint Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double-blind comparison
    A G G Turpie
    Department of Medicine, Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada
    J Thromb Haemost 5:1854-61. 2007
    ..The benefit of combined mechanical and pharmacologic methods for venous thromboembolism prevention after abdominal surgery has not been clearly established...
  26. ncbi request reprint Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy
    Alexander G G Turpie
    Hamilton Health Sciences General Hospital, Department of Medicine, 237 Barton Street East, Hamilton, Ontario, L8L 2X2, Canada
    Expert Opin Pharmacother 5:1373-84. 2004
    ..5 mg once-daily s.c. has been approved for the prevention of venous thromboembolism after major orthopaedic surgery. Fondaparinux use in extended prophylaxis (4 weeks) after hip fracture surgery has also been recently approved...
  27. ncbi request reprint Fondaparinux, the first selective factor Xa inhibitor
    Alexander G G Turpie
    Hamilton Health Sciences General Hospital, Hamilton, Ontario, Canada
    Curr Opin Hematol 10:327-32. 2003
    ..Finally, the efficacy and safety of fondaparinux in the treatment of venous thromboembolism and acute coronary syndromes appears promising...
  28. ncbi request reprint Use of selective factor Xa inhibitors in special populations
    Alexander G G Turpie
    McMaster University Hamilton Health Sciences Corporation General Site, Hamilton, Ontario, Canada
    Am J Orthop (Belle Mead NJ) 31:11-5. 2002
    ..One feature of fondaparinux is that it can be administered safely and efficaciously in a wide variety of patient populations, without the need for dosage modification...
  29. ncbi request reprint State of the art--a journey through the world of antithrombotic therapy
    Alexander G G Turpie
    Department of Medicine, HHS General Hospital, McMaster Clinic, Hamilton, Ontario, Canada
    Semin Thromb Hemost 28:3-11. 2002
    ..New data indicate that combination therapy with aspirin and a novel thienopyridine, clopidogrel, may further improve outcomes in this indication...
  30. ncbi request reprint Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies
    Alexander G G Turpie
    Department of Medicine, Hamilton Health Sciences General Hospital, 237 Barton, Hamilton, Ontario, Canada L8L 2X2
    Arch Intern Med 162:1833-40. 2002
    ..Fondaparinux, the first of a new class of synthetic selective factor Xa inhibitors, may further reduce this risk compared with currently available thromboprophylactic treatments...
  31. ncbi request reprint Direct Factor Xa and direct thrombin inhibitors: a clinical trial update
    Alexander G G Turpie
    McMaster University, Hamilton, ON, Canada
    Curr Opin Drug Discov Devel 12:497-508. 2009
    ..This review provides an update on clinical trials of the direct FXa and thrombin inhibitors...
  32. ncbi request reprint Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial
    Alexander G G Turpie
    Department of Medicine, General Division, Hamilton Health Sciences Corporation, Ontario, Hamilton, Canada
    Lancet 359:1721-6. 2002
    ..We aimed to see whether the pentasaccharide fondaparinux, the first drug of a new class of synthetic antithrombotic agents, could reduce this risk to a greater extent than other available treatments...
  33. ncbi request reprint Review of enoxaparin and its clinical applications in venous and arterial thromboembolism
    Alexander G G Turpie
    Hamilton Health Sciences, Hamilton General Hospital, 237 Barton Street East, Hamilton, Ontario, Canada, L8L 2X2
    Expert Opin Pharmacother 3:575-98. 2002
    ..Adverse events with enoxaparin are infrequent; the most common events are minor bleeding complications. It should be noted that different doses or indications are approved in each country...
  34. ncbi request reprint Setting a standard for venous thromboembolism prophylaxis
    A G Turpie
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Am J Health Syst Pharm 58:S18-23. 2001
    ..Fondaparinux sodium, a novel antithrombotic agent, is effective for the prevention of VTE, with a favorable safety profile, in patients undergoing major orthopedic surgery...
  35. ncbi request reprint Future therapeutic directions for factor Xa inhibition in the prophylaxis and treatment of thrombotic disorders
    Alexander G G Turpie
    McMaster University, Hamilton Health Sciences General Hospital, Hamilton, Ontario L8L 2X2, Canada
    Am J Health Syst Pharm 60:S20-4. 2003
    ..The orthopedic prophylactic and nonorthopedic clinical programs for fondaparinux in the management of thrombosis support the concept that targeted inhibition of coagulation is an effective advance in antithrombotic therapy...
  36. ncbi request reprint New pentasaccharides for the prophylaxis of venous thromboembolism: clinical studies
    Alexander G G Turpie
    Department of Medicine, Hamilton Health Sciences General Hospital, 237 Barton Street East, Hamilton, Ontario L8L 2X2, Canada
    Chest 124:371S-378S. 2003
    ..Fondaparinux has been recently approved for use in thromboprophylaxis after major orthopedic surgery. The clinical development of fondaparinux in other thromboprophylactic indications is ongoing...
  37. ncbi request reprint Pentasaccharide Org31540/SR90107A clinical trials update: lessons for practice
    A G Turpie
    McMaster University, Hamilton, Ontario, Canada
    Am Heart J 142:S9-15. 2001
    ..However, efficacy and safety limitations of these agents have prompted a search for alternative antithrombotic drugs...
  38. ncbi request reprint Low-molecular-weight heparins in the treatment of acute coronary syndromes
    A G Turpie
    HHSC General Division, 237 Barton St E, Hamilton, Ontario, Canada L8L 2X2
    Arch Intern Med 161:1484-90. 2001
    ..In clinical trials comparing low-molecular-weight heparin with heparin, only enoxaparin sodium has been shown to reduce the risk of coronary events in patients with non-ST segment elevation acute coronary ischemia...
  39. ncbi request reprint A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery
    Alexander G G Turpie
    Department of Medicine, Hamilton Health Sciences General Hospital, Hamilton, Ontario, Canada
    J South Orthop Assoc 11:182-8. 2002
    ..4%. The overall incidence of clinically relevant bleeding was low and did not differ between the two groups. The benefit of fondaparinux was consistent across all types of surgery and all subgroups...
  40. ncbi request reprint Bilateral vs. ipsilateral venography as the primary efficacy outcome measure in thromboprophylaxis clinical trials: a systematic review
    A Y Y Lee
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    J Thromb Haemost 2:1752-9. 2004
    ....
  41. ncbi request reprint Low molecular weight heparins in the treatment of unstable angina
    W Ageno
    McMaster University, Hamilton, Canada
    Minerva Cardioangiol 50:643-51. 2002
    ..Direct comparisons are now required to determine the superiority of one compound over another...
  42. pmc Approach to managing musculoskeletal pain: acetaminophen, cyclooxygenase-2 inhibitors, or traditional NSAIDs?
    Richard H Hunt
    Division of Gastroenterology at McMaster University in Hamilton, Ont
    Can Fam Physician 53:1177-84. 2007
    ..To provide family physicians and pharmacists with practical, evidence- and expertise-based guidance on choosing the safest approach to using analgesics to manage patients with musculoskeletal pain...
  43. ncbi request reprint Fondaparinux
    Alexander G G Turpie
    Department of Medicine, Hamilton Health Sciences Hamilton General Hospital and McMaster University, Hamilton, Ontario, Canada
    J Am Acad Orthop Surg 12:371-5. 2004
  44. ncbi request reprint Prevention of venous thromboembolism among hospitalized medical patients
    Samuel Z Goldhaber
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 111:e1-3. 2005
  45. ncbi request reprint Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients
    Paul T Vaitkus
    Cardiology Division, College of Medicine, University of Illinois at Chicago, 840 S Wood St, Chicago, Illinois 60612, USA
    Thromb Haemost 93:76-9. 2005
    ..In conclusion, the high mortality rate in patients with asymptomatic proximal DVT underscores its clinical relevance and supports targeting of asymptomatic proximal DVT as an appropriate endpoint in clinical trials of thromboprophylaxis...
  46. doi request reprint Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN Registry)
    Alex C Spyropoulos
    Lovelace Medical Center, Albuquerque, New Mexico, USA
    Am J Cardiol 102:883-9. 2008
    ....
  47. doi request reprint Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty
    Michael R Lassen
    Nordsjaellands Hospital, Hørsholm, Denmark
    N Engl J Med 358:2776-86. 2008
    ..We investigated the efficacy of rivaroxaban, an orally active direct factor Xa inhibitor, in preventing venous thrombosis after total knee arthroplasty...
  48. doi request reprint SR123781A: a new once-daily synthetic oligosaccharide anticoagulant for thromboprophylaxis after total hip replacement surgery: the DRIVE (Dose Ranging Study in Elective Total Hip Replacement Surgery) study
    Michael R Lassen
    Hørsholm Hospital, Hørsholm, Denmark
    J Am Coll Cardiol 51:1498-504. 2008
    ..This study assessed the dose response of SR123781A for the prevention of venous thromboembolism (VTE) in patients undergoing total hip replacement (THR) surgery...
  49. ncbi request reprint Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery
    Wolfgang Mueck
    Clinical Pharmacology, Bayer HealthCare AG, Aprather Weg 18a, Wuppertal, Germany
    Clin Pharmacokinet 47:203-16. 2008
    ....
  50. ncbi request reprint Pentasaccharides
    Alexander G G Turpie
    Hamilton Health Sciences Hamilton General Hospital, 237 Barton Street East, Hamilton, Ontario, L8L 2X2 Canada
    Semin Hematol 39:158-71. 2002
    ....
  51. ncbi request reprint Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism
    Kenneth A Bauer
    VA Boston Healthcare System and Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Curr Opin Pulm Med 8:398-404. 2002
    ..Fondaparinux also appears to be a very promising candidate for the treatment of patients with existing VTE...
  52. ncbi request reprint Benefit of selective factor inhibition
    Alexander G G Turpie
    Hamilton Health Sciences Hamilton General Hospital, Hamilton, Ontario, Canada
    Semin Thromb Hemost 28:49-50. 2002
  53. ncbi request reprint Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study
    Raza Alikhan
    Academic Department of Surgery, Guy s, King s, and St Thomas School of Medicine, London, England
    Arch Intern Med 164:963-8. 2004
    ..There is limited information about risk factors for venous thromboembolism (VTE) in acutely ill hospitalized general medical patients...
  54. ncbi request reprint The safety of antithrombotic therapy during pregnancy
    Walter Ageno
    Department of Internal Medicine, UO Medicina I, Ospedale di Circolo, Varese, Italy
    Expert Opin Drug Saf 3:113-8. 2004
    ..Full-dose UFH is recommended in the first trimester and after week 36. The use of LMWH as an alternative to UFH is still a matter of debate, because inadequate data are available...
  55. ncbi request reprint Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients
    Alain Leizorovicz
    Unite de Pharmacologie Clinique, Universite Claude Bernard Lyon I, Lyon, France
    Circulation 110:874-9. 2004
    ....
  56. pmc New advances in the management of acute coronary syndromes: 4. Low-molecular-weight heparins
    Walter Ageno
    Department of Internal Medicine, University of Insubria, Varese, Italy
    CMAJ 166:919-24. 2002
  57. ncbi request reprint Fondaparinux and prevention of venous thromboembolism after orthopaedic surgery
    Alexander G G Turpie
    Lancet 362:1582-3. 2003
  58. ncbi request reprint Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison
    Michael Rud Lassen
    Department of Orthopaedics, University Hospital of Copenhagen Hillerød, DK 3400, Hillerød, Denmark
    Lancet 359:1715-20. 2002
    ..We aimed to assess the ability of the pentasaccharide fondaparinux, the first of a new class of synthetic antithrombotic agents, to further reduce this risk...
  59. ncbi request reprint Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada
    Susan R Kahn
    Department of Medicine, McGill University, SMBD Jewish General Hospital, Canada
    Thromb Res 119:145-55. 2007
    ..Venous thromboembolism (VTE) prophylaxis in acutely ill medical patients has been shown to be safe and effective. Underutilization of this patient safety practice may result in avoidable mortality and morbidity...
  60. ncbi request reprint Optimizing prophylaxis of venous thromboembolism
    Alexander G G Turpie
    Hamilton Health Sciences Hamilton General Hospital, Hamilton, Ontario, Canada
    Semin Thromb Hemost 28:25-32. 2002
    ..It has been suggested that fondaparinux's superior efficacy may be related to its ability to initiate selective inhibition of factor Xa and its predictable linear pharmacokinetics...
  61. pmc ABC of antithrombotic therapy: Venous thromboembolism: treatment strategies
    Alexander G G Turpie
    Department of Medicine, McMaster University, Hamilton, Canada
    BMJ 325:948-50. 2002
  62. pmc Valvar heart disease and prosthetic heart valves
    Ira Goldsmith
    University Department of Medicine, City Hospital, Birmingham
    BMJ 325:1228-31. 2002
  63. ncbi request reprint Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM study
    Russell D Hull
    Thrombosis Research Unit, Foothills Hospital, University of Calgary, Room 601 South Tower, 1403 29th Street NW, Calgary, T2N 2T9, Alberta, Canada
    J Thromb Thrombolysis 22:31-8. 2006
    ....
  64. ncbi request reprint Clinical trials of deep vein thrombosis prophylaxis in medical patients
    Walter Ageno
    Department of Clinical Medicine, Ospedale di Circolo University of Insubria Varese, Italy
    Clin Cornerstone 7:16-22. 2005
    ..The results of these studies support the evidence-based recommendations for systematic use of thromboprophylaxis in this setting...
  65. ncbi request reprint Correlation of plasma coagulation parameters with thromboprophylaxis, patient characteristics, and outcome in the MEDENOX study
    Louis Desjardins
    Service hématologie, CHU Laval, Ste Foy, Quebec, Canada
    Arch Pathol Lab Med 128:519-26. 2004
    ..Plasma anti-Xa and anti-IIa activities correlate with the dose of low-molecular-weight heparin, and D-dimer and thrombin-antithrombin complexes are markers of procoagulant activity...
  66. ncbi request reprint Flexibility in administration of fondaparinux for prevention of symptomatic venous thromboembolism in orthopaedic surgery
    Clifford W Colwell
    Shiley Center for Orthopaedic Research and Education at Scripps Clinic, La Jolla, California 92037 1030, USA
    J Arthroplasty 21:36-45. 2006
    ..2% and 0.7% [P = .19], and 1.4% and 2.0% [P = .31], respectively). Delaying initiation of fondaparinux prophylaxis provides an option after total joint arthroplasty with preserved efficacy and safety...
  67. pmc Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial
    Alexander T Cohen
    Department of Surgery, Guy s, King s, and St Thomas s School of Medicine, London SE5 9PJ
    BMJ 332:325-9. 2006
    ..To determine the efficacy and safety of the anticoagulant fondaparinux in older acute medical inpatients at moderate to high risk of venous thromboembolism...
  68. ncbi request reprint A randomized pilot study of dalteparin versus unfractionated heparin during percutaneous coronary interventions
    Madhu K Natarajan
    Division of Cardiology, Department of Medicine, Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada
    Am Heart J 151:175. 2006
    ..This study examined the relative effects of dalteparin and UFH on coagulation and angiographic and clinical indices during PCI...
  69. ncbi request reprint Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients
    Alexander T Cohen
    Vascular Medicine, Department of Surgery, Guy s, King s and St Thomas School of Medicine, London, UK
    Thromb Haemost 94:750-9. 2005
    ..These medical conditions and risk factors are included in a risk-assessment model which is hoped will provide a simple means of assisting clinicians in deciding whether thromboprophylaxis should be used in an individual patient...
  70. ncbi request reprint Unstable angina and non-ST-elevation myocardial infarction: initial antithrombotic therapy and early invasive strategy
    Christopher P Cannon
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Mass 02115, USA
    Circulation 107:2640-5. 2003
  71. ncbi request reprint The clinical challenge of bridging anticoagulation with low-molecular-weight heparin in patients with mechanical prosthetic heart valves: an evidence-based comparative review focusing on anticoagulation options in pregnant and nonpregnant patients
    Niranjan Seshadri
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am Heart J 150:27-34. 2005
    ....
  72. ncbi request reprint Perioperative management of patients receiving oral anticoagulants: a systematic review
    Andrew S Dunn
    Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    Arch Intern Med 163:901-8. 2003
    ..The safety and efficacy of various management strategies for patients receiving oral anticoagulants (OACs) who need to undergo surgery or invasive procedures are unknown...
  73. ncbi request reprint Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial
    Nils Kucher
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Arch Intern Med 165:341-5. 2005
    ..We were concerned that a fixed rather than a weight-based dosing regimen of dalteparin sodium to prevent venous thromboembolism (VTE) might result in decreased efficacy in obese patients and decreased safety in elderly patients...
  74. ncbi request reprint Early recovery and functional outcome are related with causal stroke subtype: data from the tinzaparin in acute ischemic stroke trial
    Nikola Sprigg
    Institute of Neuroscience, University of Nottingham, United Kingdom
    J Stroke Cerebrovasc Dis 16:180-4. 2007
    ..Baseline severity and causal subtype are predictors of outcome in ischemic stroke. We used data from the Tinzaparin in Acute Ischemic Stroke Trial (TAIST) to further assess the relationship among stroke subtype, early recovery, and outcome...
  75. ncbi request reprint Thromboprophylaxis with dalteparin in medical patients: which patients benefit?
    Alexander T Cohen
    Department of Surgery, King s College Hospital, Bessemer Road, London SE5 9PJ, UK
    Vasc Med 12:123-7. 2007
    ..Our findings, therefore, support the broad application of thromboprophylaxis in acutely ill hospitalized medical patients...
  76. ncbi request reprint Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism
    Victor F Tapson
    Division of Pulmonary and Critical Care, Box 31175, Room 351 Bell Building, Duke University Medical Center, Durham, NC 27710, USA
    Chest 132:936-45. 2007
    ..Our aim was to characterize the clinical practices for VTE prophylaxis in acutely ill hospitalized medical patients enrolled in the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE)...
  77. ncbi request reprint Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies
    William D Fisher
    McGill University Health Centre, 1650 Cedar Avenue, Montreal, Quebec, H3G 1A4, Canada
    Thromb Haemost 97:931-7. 2007
    ..Overall, rivaroxaban total daily doses of 5-20 mg had the most favorable balance of efficacy and safety, relative to enoxaparin, for the prevention of VTE after major orthopaedic surgery...
  78. ncbi request reprint Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study
    Raza Alikhan
    Academic Department of Surgery, Guy s, King s, St Thomas School of Medicine, London, UK
    Blood Coagul Fibrinolysis 14:341-6. 2003
    ..22 (95% CI, 0.09-0.51); immobility, 0.53 (95% CI, 0.14-1.72); previous VTE, 0.49 (95% CI, 0.15-1.68); and cancer, 0.50 (95%o CI, 0.14-1.72). The beneficial effects of enoxaparin extend to a wide range of acutely ill medical patients...
  79. ncbi request reprint Stroke severity, early recovery and outcome are each related with clinical classification of stroke: data from the 'Tinzaparin in Acute Ischaemic Stroke Trial' (TAIST)
    Nikola Sprigg
    Institute of Neuroscience, University of Nottingham, Nottingham, UK
    J Neurol Sci 254:54-9. 2007
    ..We used data from the 'Tinzaparin in Acute Ischaemic Stroke Trial' (TAIST) to assess the relationship between stroke severity, early recovery, outcome and OCSP syndrome...
  80. ncbi request reprint A new antithrombotic strategy, the selective inhibition of coagulation factors, and its importance to the orthopedic specialist
    Kenneth A Bauer
    Department of Medicine, VA Boston Healthcare System and Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J South Orthop Assoc 11:197-202. 2002
    ..Fondaparinux has demonstrated its efficacy compared to a widely used low-molecular-weight heparin in a number of thromboprophylaxis trials after major orthopedic surgery and is approved for use in this setting...
  81. ncbi request reprint Perioperative bridging interruption with heparin for the patient receiving long-term anticoagulation
    Alex C Spyropoulos
    Clinical Thrombosis Center Lovelace Medical Center Albuquerque, New Mexico 87108, USA
    Curr Opin Pulm Med 11:373-9. 2005
    ....